HRP20161740T1 - Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b - Google Patents
Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence bInfo
- Publication number
- HRP20161740T1 HRP20161740T1 HRP20161740TT HRP20161740T HRP20161740T1 HR P20161740 T1 HRP20161740 T1 HR P20161740T1 HR P20161740T T HRP20161740T T HR P20161740TT HR P20161740 T HRP20161740 T HR P20161740T HR P20161740 T1 HRP20161740 T1 HR P20161740T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- region
- heavy chain
- light chain
- influenza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161572417P | 2011-07-14 | 2011-07-14 | |
| EP11173953 | 2011-07-14 | ||
| PCT/EP2012/063637 WO2013007770A1 (en) | 2011-07-14 | 2012-07-12 | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| EP12735516.2A EP2731967B1 (en) | 2011-07-14 | 2012-07-12 | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161740T1 true HRP20161740T1 (hr) | 2017-02-10 |
Family
ID=47505543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161740TT HRP20161740T1 (hr) | 2011-07-14 | 2012-07-12 | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8961978B2 (enExample) |
| EP (1) | EP2731967B1 (enExample) |
| JP (1) | JP5683752B2 (enExample) |
| KR (1) | KR101941724B1 (enExample) |
| CN (1) | CN103906763B (enExample) |
| AU (1) | AU2012282504B2 (enExample) |
| BR (1) | BR112014000263B1 (enExample) |
| CA (1) | CA2838999C (enExample) |
| DK (1) | DK2731967T3 (enExample) |
| EA (1) | EA027054B1 (enExample) |
| ES (1) | ES2608321T3 (enExample) |
| HR (1) | HRP20161740T1 (enExample) |
| IL (1) | IL230222A (enExample) |
| IN (1) | IN2014CN00953A (enExample) |
| MX (1) | MX346206B (enExample) |
| MY (1) | MY166282A (enExample) |
| PH (1) | PH12013502479A1 (enExample) |
| WO (1) | WO2013007770A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8961978B2 (en) | 2011-07-14 | 2015-02-24 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
| WO2013079473A1 (en) | 2011-11-28 | 2013-06-06 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
| CN104302321A (zh) | 2011-12-05 | 2015-01-21 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| CA2906676A1 (en) * | 2013-03-14 | 2014-09-25 | Contrafect Corporation | Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy |
| US9649375B2 (en) | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| KR20140118682A (ko) * | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| BR112015029635B1 (pt) | 2013-05-30 | 2023-05-02 | Janssen Vaccines & Prevention B.V | Polipeptídeo do domínio de haste da hemaglutinina da gripe e composição |
| LT3052192T (lt) * | 2013-10-02 | 2020-12-10 | Medimmune, Llc | Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas |
| RU2682049C2 (ru) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
| US10639370B2 (en) | 2014-02-04 | 2020-05-05 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| JP6712428B2 (ja) * | 2014-02-04 | 2020-06-24 | コントラフェクト コーポレイション | インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法 |
| BR112016018313A8 (pt) | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | Moléculas de ligação multiespecíficas iga |
| BR112016022113A2 (pt) * | 2014-03-27 | 2017-10-31 | Genentech Inc | anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso |
| KR101628331B1 (ko) * | 2014-03-28 | 2016-06-08 | 주식회사 녹십자엠에스 | 인플루엔자 a 바이러스 특이적 단클론 항체 및 이를 이용한 인플루엔자 감염 치료 및 진단 방법 |
| JP7094103B2 (ja) | 2014-07-10 | 2022-07-01 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | インフルエンザウイルスワクチンおよびその使用 |
| EP3166962B1 (en) | 2014-07-10 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| AU2015289805B2 (en) * | 2014-07-15 | 2020-06-25 | Humabs Biomed Sa | Neutralizing anti-influenza B antibodies and uses thereof |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| WO2016124682A1 (en) | 2015-02-05 | 2016-08-11 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza neuraminidase |
| CA2975655C (en) * | 2015-02-05 | 2023-09-19 | Janssen Vaccines & Prevention B.V. | Binding molecules directed against influenza hemagglutinin and uses thereof |
| EP3280730B1 (en) * | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| CA2985402A1 (en) | 2015-05-11 | 2016-11-17 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing peptidomimetic compounds |
| US11535665B2 (en) | 2015-05-13 | 2022-12-27 | The Trustees Of The University Of Pennsylvania | AAV-mediated expression of anti-influenza antibodies and methods of use thereof |
| PL3303384T3 (pl) | 2015-06-01 | 2022-01-03 | Medimmune, Llc | Neutralizujące cząsteczki wiążące przeciw grypie i ich zastosowania |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CA3010313A1 (en) | 2016-01-13 | 2017-07-20 | Medimmune, Llc | Method of treating influenza a |
| CA3015347A1 (en) | 2016-02-24 | 2017-08-31 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| WO2017148889A1 (en) | 2016-03-01 | 2017-09-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza b neuraminidase |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2018038096A1 (ja) * | 2016-08-23 | 2018-03-01 | 国立大学法人東京大学 | モノクローナル抗体又はその抗原結合フラグメント及びその使用 |
| AU2017350304B2 (en) | 2016-10-27 | 2022-03-03 | Janssen Vaccines & Prevention B.V. | Influenza virus neutralizing compounds |
| EP3574008B1 (en) * | 2017-01-27 | 2023-11-08 | National Research Council of Canada | Hemagglutinin-specific antibodies and uses thereof |
| US11040963B2 (en) | 2017-02-02 | 2021-06-22 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibitions |
| WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| WO2018160573A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
| WO2018160582A1 (en) | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| SMT202200354T1 (it) | 2018-01-23 | 2022-09-14 | Janssen Vaccines & Prevention Bv | Vaccino per virus dell'influenza e suoi usi |
| JP7372925B2 (ja) | 2018-01-26 | 2023-11-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インフルエンザヘマグルチニンに対するヒト抗体 |
| EP3946613A1 (en) | 2019-03-25 | 2022-02-09 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CA3152957A1 (en) * | 2019-09-05 | 2021-03-11 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
| WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
| US11175293B1 (en) | 2021-01-04 | 2021-11-16 | University Of Utah Research Foundation | Rapid assay for detection of SARS-CoV-2 antibodies |
| CN116761605A (zh) * | 2021-02-04 | 2023-09-15 | 四川海思科制药有限公司 | Ha抑制剂化合物的盐及晶型 |
| JP2025512515A (ja) | 2022-04-14 | 2025-04-17 | インビジシールド テクノロジーズ リミテッド | インフルエンザ感染症を予防又は治療するための組成物 |
| WO2024104947A2 (en) | 2022-11-14 | 2024-05-23 | Janssen Vaccines & Prevention B.V. | Influenza b virus vaccines and uses thereof |
| CN116589566A (zh) * | 2022-11-18 | 2023-08-15 | 昆明医科大学第一附属医院 | 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用 |
| US20250090650A1 (en) | 2023-09-06 | 2025-03-20 | Sanofi | Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| CA2267139A1 (en) | 1996-10-08 | 1998-04-16 | Ton Logtenberg | Methods and means for selecting peptides and proteins having specific affinity for a target |
| WO2000063403A2 (en) | 1999-04-15 | 2000-10-26 | Crucell Holland B.V. | Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
| DK1402025T3 (da) | 2001-06-15 | 2006-06-06 | Crucell Holland Bv | Kimære fager |
| MY170607A (en) * | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| FR2921928B1 (fr) * | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
| KR20110049802A (ko) | 2008-07-25 | 2011-05-12 | 인스티튜트 포 리서치 인 바이오메드슨 | 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도 |
| EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
| US8470327B2 (en) | 2009-05-11 | 2013-06-25 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
| US8961978B2 (en) | 2011-07-14 | 2015-02-24 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
-
2012
- 2012-07-12 US US14/126,404 patent/US8961978B2/en active Active
- 2012-07-12 DK DK12735516.2T patent/DK2731967T3/en active
- 2012-07-12 CN CN201280034558.0A patent/CN103906763B/zh active Active
- 2012-07-12 JP JP2014519551A patent/JP5683752B2/ja active Active
- 2012-07-12 IN IN953CHN2014 patent/IN2014CN00953A/en unknown
- 2012-07-12 EA EA201490288A patent/EA027054B1/ru not_active IP Right Cessation
- 2012-07-12 MY MYPI2014700068A patent/MY166282A/en unknown
- 2012-07-12 MX MX2014000373A patent/MX346206B/es active IP Right Grant
- 2012-07-12 AU AU2012282504A patent/AU2012282504B2/en active Active
- 2012-07-12 ES ES12735516.2T patent/ES2608321T3/es active Active
- 2012-07-12 BR BR112014000263-0A patent/BR112014000263B1/pt active IP Right Grant
- 2012-07-12 CA CA2838999A patent/CA2838999C/en active Active
- 2012-07-12 EP EP12735516.2A patent/EP2731967B1/en active Active
- 2012-07-12 KR KR1020137035132A patent/KR101941724B1/ko active Active
- 2012-07-12 HR HRP20161740TT patent/HRP20161740T1/hr unknown
- 2012-07-12 PH PH1/2013/502479A patent/PH12013502479A1/en unknown
- 2012-07-12 WO PCT/EP2012/063637 patent/WO2013007770A1/en not_active Ceased
-
2013
- 2013-12-29 IL IL230222A patent/IL230222A/en active IP Right Grant
-
2015
- 2015-01-14 US US14/597,016 patent/US9593159B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2608321T3 (es) | 2017-04-07 |
| PH12013502479A1 (en) | 2014-01-20 |
| AU2012282504B2 (en) | 2017-07-20 |
| US20140120113A1 (en) | 2014-05-01 |
| MY166282A (en) | 2018-06-25 |
| JP2014527403A (ja) | 2014-10-16 |
| CA2838999A1 (en) | 2013-01-17 |
| AU2012282504A1 (en) | 2014-02-06 |
| NZ618530A (en) | 2016-05-27 |
| KR20140095017A (ko) | 2014-07-31 |
| US20150274811A1 (en) | 2015-10-01 |
| US8961978B2 (en) | 2015-02-24 |
| KR101941724B1 (ko) | 2019-01-23 |
| IN2014CN00953A (enExample) | 2015-04-10 |
| DK2731967T3 (en) | 2017-01-16 |
| BR112014000263B1 (pt) | 2022-01-18 |
| CN103906763A (zh) | 2014-07-02 |
| MX346206B (es) | 2017-03-09 |
| JP5683752B2 (ja) | 2015-03-11 |
| EP2731967A1 (en) | 2014-05-21 |
| EA201490288A1 (ru) | 2014-05-30 |
| IL230222A (en) | 2017-09-28 |
| EA027054B1 (ru) | 2017-06-30 |
| MX2014000373A (es) | 2014-03-31 |
| CA2838999C (en) | 2021-02-16 |
| CN103906763B (zh) | 2016-10-12 |
| BR112014000263A2 (pt) | 2017-02-14 |
| EP2731967B1 (en) | 2016-10-12 |
| US9593159B2 (en) | 2017-03-14 |
| WO2013007770A1 (en) | 2013-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| HRP20201975T1 (hr) | Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| JP2011528901A5 (enExample) | ||
| JP2010521147A5 (enExample) | ||
| PH12016500859A1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| HRP20130163T1 (hr) | Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2015522252A5 (enExample) | ||
| JP6371222B2 (ja) | インフルエンザの受動免疫用抗体 | |
| JP2016503413A5 (enExample) | ||
| SI3042917T1 (en) | Anti-n3pglu amyloid beta peptide antibodies and uses thereof | |
| JP2014237714A5 (enExample) | ||
| JP2013531993A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2010502207A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| CR20160319A (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este | |
| RU2017145268A (ru) | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов | |
| PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| EA201692530A1 (ru) | Цитотоксические пептиды и их конъюгаты | |
| HRP20191608T1 (hr) | Proteini s ponavljajućim dipeptidom kao terapeutsko ciljno mjesto kod neurodegenerativnih bolesti s ekspanzijom ponavljajućeg heksanukleotida | |
| JP2014205674A5 (enExample) |